Listen
DAIVOBET
-
Opinions on drugs -
Posted on
May 09 2007
- Updated on
Jun 20 2007
Reason for request
inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of the indication
-
Clinical Benefit
| Substantial |
The actual benefit of this medicinal product in the case of repeated use beyond 4 weeks of treatment and in compliance with the correct usage is substantial. |
Clinical Added Value
| minor |
The Committee points out that in the case of initial treatment for psoriasis limited to 4 weeks, “DAIVOBET provides a level IV (minor) improvement in actual benefit in terms of efficacy, speed of action and reduction in adverse effects in relation to the comparators used in clinical trials (calcipotriol, betamethasone and tacalcitol)”. |
| no clinical added value |
In a situation where treatment is extended beyond 4 weeks, DAIVOBET does not bring any improvement in actual benefit in relation to DAIVONEX. |
Documents
Contact Us
Évaluation des médicaments
